Scottish Widows has begun investing workplace pension capital in UK venture-growth businesses through its CG Scottish Widows Growth Long-Term Asset Fund (LTAF), with initial investments targeting companies developing technologies in quantum computing, advanced batteries and AI-enabled healthcare.
Aberdeen Investments, which manages the fund’s growth sub-fund, has appointed IP Group to manage a dedicated UK venture-growth portfolio, connecting long-term institutional capital with high-growth British businesses.
The initial investment pipeline includes Oxford Quantum Circuits, which develops commercially available quantum computing systems; Quantum Motion, which is developing scalable silicon-based quantum computers; Nyobolt, an advanced battery technology company; and Genomics Limited, which applies artificial intelligence, machine learning and genetic datasets to preventative healthcare and drug discovery.
The fund is among the first UK workplace pension propositions to actively allocate members’ capital to domestic venture growth, according to the companies involved.
The mandate aims to address a funding gap for UK businesses seeking follow-on investment to commercialise technologies and expand their operations. It also provides workplace pension savers with exposure to private markets, an area traditionally associated with institutional investors.
Peter Fitzgerald, chief investment officer at Scottish Widows, said: "We believe pension savers should be able to benefit from the growth and innovation taking place across the UK. Our proposition helps connect our workplace pension customers’ long-term savings with some of Britain’s most innovative, high-growth companies, giving them access to investment opportunities that have traditionally been available mainly to institutional investors."
Nalaka De Silva, head of Private Markets Solutions at Aberdeen Investments, added: "We are delighted to have partnered with IP Group to manage this portfolio on behalf of the Scottish Widows Growth LTAF. The UK has no shortage of scientific excellence and does not lack entrepreneurship or talent to develop globally relevant ideas.
"What competitive companies have lacked is sufficient pools of patient domestic capital to help them expand and grow. This partnership turns intent into investment: We are extremely proud to deliver one of the first active allocations by a UK DC workplace pension proposition to back British science and technology companies for the long-term benefit of pension members.”











